StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report released on Thursday. The firm issued a sell rating on the stock.
Ayala Pharmaceuticals Stock Up 4.6 %
NASDAQ:ADXS opened at $0.56 on Thursday. Ayala Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $1.95. The stock’s fifty day moving average is $0.67 and its two-hundred day moving average is $0.72. The company has a market capitalization of $5.97 million, a P/E ratio of -0.07 and a beta of 1.63.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported ($2.96) earnings per share (EPS) for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
See Also
- Five stocks we like better than Ayala Pharmaceuticals
- How to Invest in the Best Canadian Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- Stock Market Upgrades: What Are They?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
